Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Mistretta

Pulmonary Disease Richmond, VA Medical Doctor

NPI 1003832817 CMS profile 45404

6600 W Broad St Ste 300, Richmond, VA 23230

Open in the dashboard

General payments

$12,666

625 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Mistretta of Richmond, VA is reported in the CMS Open Payments database as having received $12,666 across 625 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,739 114
2024 General $2,397 117
2023 General $2,192 103
2022 General $1,677 93
2021 General $1,630 87
2020 General $477 33
2019 General $1,554 78

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Mistretta
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Michael Mistretta were reported at $2,739. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Michael Mistretta Pulmonary Disease median Middle half National median
2019 $1,554 $377 $109–$1,340 $163
2020 $477 $230 $56–$907 $114
2021 $1,630 $269 $68–$1,072 $132
2022 $1,677 $390 $100–$1,457 $149
2023 $2,192 $419 $114–$1,659 $160
2024 $2,397 $476 $123–$1,818 $164
2025 $2,739 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $2,187 161 payments
  2. AstraZeneca Pharmaceuticals LP $2,106 53 payments
  3. Grifols USA, LLC $980 35 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $902 47 payments
  5. Genentech USA, Inc. $770 56 payments
  6. Amgen Inc. $588 30 payments
  7. Regeneron Healthcare Solutions, Inc. $521 22 payments
  8. Genzyme Corporation $480 26 payments
  9. Mallinckrodt Hospital Products Inc. $412 18 payments
  10. Insmed, Inc. $386 25 payments
  11. Other $3,335 152 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $12,161 620 payments
  2. Consulting Fee $275 1 payment
  3. Education $231 4 payments
Products named General payments · program years 2019–2025
  1. FASENRA $1,389 30 payments
  2. TRELEGY ELLIPTA $990 96 payments
  3. Prolastin-C Liquid $952 34 payments
  4. NUCALA $894 47 payments
  5. Xolair $766 55 payments
  6. TEZSPIRE Respiratory $646 11 payments
  7. BREZTRI $630 10 payments
  8. TEZSPIRE Inflammation $573 29 payments
  9. OFEV $444 18 payments
  10. DUPIXENT $424 23 payments
  11. Other $6,999 333 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 37 drugs

Part D claims

3,606

Median for Pulmonary Disease: 936

Drug cost

$1,203,643

Median for Pulmonary Disease: $487,987

Branded share of claims

68.5%

Median for Pulmonary Disease: 69.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 704 $551,925
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 229 $183,270
Breo Ellipta Fluticasone/Vilanterol Brand 175 $86,295
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 87 $56,673
Spiriva Respimat Tiotropium Bromide Brand 80 $55,509
Symbicort Budesonide/Formoterol Fumarate Brand 106 $36,593
Stiolto Respimat Tiotropium Br/Olodaterol Hcl Brand 40 $35,104
Xarelto Rivaroxaban Brand 27 $21,983
Spiriva Handihaler Tiotropium Bromide Brand 24 $19,098
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 111 $18,428

The 10 drugs with the highest cost, of 37 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,233 Part D prescribers listed as Pulmonary Disease; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$406,316

Of which drugs: $185,036

Medicare patients

887

Average age 76

Services billed

12,409

549 women, 338 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
COPD 52%
Arthritis 50%
Ischemic heart disease 41%
Diabetes 29%
Depression 28%
Heart failure 27%
Chronic kidney disease 27%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, omalizumab, 5 mg J2357 Office 27 2,715 $81,699
Injection, mepolizumab, 1 mg J2182 Office 17 2,600 $62,055

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUCALA
$289 — 2,600
TEZSPIRE
$253 — —
FASENRA
$219 — —
TRELEGY ELLIPTA
$205 704 —
PURIFIED CORTROPHIN GEL
$168 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

625 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record